Labomar Logo

Labomar

A CDMO developing custom supplements, medical devices & cosmetics for third-party clients.

LBM | XMIL

Overview

Corporate Details

ISIN(s):
IT0005421646
LEI:
815600BD66DA7878FF03
Country:
Italy
Address:
VIA NAZARIO SAURO, 35/I, 31036 ISTRANA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Labomar is a full-service Contract Development and Manufacturing Organization (CDMO) founded in 1998. The company specializes in the research, development, and production of nutraceuticals, food supplements, medical devices, foods for special medical purposes, and cosmetics for third-party clients. Operating as an innovation-driven B2B partner, Labomar offers a 'one-stop-shop' service, from product conception to finished goods. It leverages patented and state-of-the-art technologies to create high-quality, bespoke solutions in various pharmaceutical forms. The company also provides personalized advice on key European industry directives and regulations. As a certified B Corporation, Labomar is committed to creating safe and effective products that enhance personal wellbeing.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-09-06 14:28
Delisting Announcement
Comunicato Procedura congiunta e revoca
Italian 282.1 KB
2023-08-31 19:53
M&A Activity
Comunicato ex art. 41, comma 2, lett. c) RE
Italian 282.5 KB
2023-08-29 17:19
Delisting Announcement
Comunicato Risultati Definitivi Sell-Out
Italian 300.3 KB
2023-08-28 17:56
Delisting Announcement
Comunicato Risultati Provvisori Sell-Out
Italian 301.7 KB
2023-08-25 17:56
M&A Activity
Comunicato adesioni Sell-Out terza settimana
Italian 302.1 KB
2023-08-18 18:16
Related Party Transaction
Comunicato Adesioni Sell Out Seconda Settimana
Italian 300.8 KB
2023-08-11 18:04
Delisting Announcement
Comunicato adesioni Sell-Out prima settimana
Italian 303.6 KB
2023-08-04 23:17
M&A Activity
Comunicato ex art. 41, comma 2, lett. c) RE
Italian 687.4 KB
2023-08-04 20:09
Major Shareholding Notification
Comunicato Azionista Significativo LBM Next S.p.A.
Italian 398.1 KB
2023-08-04 20:07
Major Shareholding Notification
Comunicato Azionista Significativo_conferimento LBM Holding
Italian 397.5 KB
2023-08-04 20:06
Major Shareholding Notification
Comunicato Azionista Significativo_Master Lab
Italian 398.3 KB
2023-08-04 20:03
Major Shareholding Notification
Comunicato Azionista Significativo_CCP
Italian 396.9 KB
2023-08-02 19:34
M&A Activity
Comunicato risultati OPA definitivi
Italian 783.8 KB
2023-08-01 18:07
Related Party Transaction
Comunicato ex art. 41, comma 2, lett. c) RE
Italian 285.3 KB
2023-07-31 18:53
M&A Activity
Comunicato risultati OPA provvisori
Italian 308.4 KB

Automate Your Workflow. Get a real-time feed of all Labomar filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Labomar

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Labomar via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
ChoA Pharmaceutical Co., LTD. Logo
Global manufacturer of OTC medicines and health supplements distributed through pharmacies.
South Korea 034940
CHUGAI PHARMACEUTICAL CO., LTD. Logo
An R&D pharma leader in Japan creating innovative drugs via antibody engineering technology.
Japan 4519
Cinclus Pharma Holding AB Logo
Clinical-stage pharma developing a next-gen P-CAB drug for severe GERD patients.
Sweden CINPHA
Circio Holding ASA Logo
Developing circular RNA vector tech and immunotherapies for gene and cell therapies.
Norway CRNA
CJ Bioscience Logo
Develops microbiome therapeutics for oncology & IBD using an AI drug discovery platform.
South Korea 311690
CKD Bio Corp. Logo
Develops and manufactures probiotics & APIs using fermentation, also offering cGMP CMO services.
South Korea 063160
CMG Pharmaceutical Co., Ltd. Logo
Develops and manufactures prescription drugs, specializing in Oral Thin Film (OTF) technology.
South Korea 058820
co.don AG Logo
Develops personalized cartilage cell transplants for minimally invasive joint repair.
Germany CNW
Compugen Ltd. Logo
Uses AI to discover and develop novel antibody immunotherapies for hard-to-treat cancers.
Israel CGEN
CORESTEMCHEMON Inc. Logo
Develops stem cell therapies & provides preclinical CRO services to pharma & biotech.
South Korea 166480

Talk to a Data Expert

Have a question? We'll get back to you promptly.